Literature DB >> 11470554

Cholinergic systems and schizophrenia: primary pathology or epiphenomena?

T M Hyde1, J M Crook.   

Abstract

Post mortem schizophrenia research has been driven first by the dopamine and then the glutamate hypotheses. These hypotheses posit primary pathology in pathways dependent upon dopamine or glutamate neurotransmission. Although the dopamine and glutamate hypotheses retain considerable theoretical strength, neurobiological findings of altered dopamine or glutamate activity in schizophrenia do not explain all features of this disorder. A more synthetic approach would suggest that focal pathological change in either the prefrontal cortex or mesial temporal lobe leads to neurochemical changes in multiple neurotransmitter systems. Despite the limited experimental evidence for abnormal cholinergic neurotransmission in psychiatric disorders, increased understanding of the role of acetylcholine in the human brain and its relationship to other neurotransmitter systems has led to a rapidly growing interest in the cholinergic system in schizophrenia. This review focuses on the basic anatomy of the mammalian cholinergic system, and its possible involvement in the neurobiology of schizophrenia. Summaries of cholinergic cell groups, projection pathways, and receptor systems, in the primate and human brain, are followed by a brief discussion of the functional correlations between aberrant cholinergic neurotransmission and the signs and symptoms of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11470554     DOI: 10.1016/s0891-0618(01)00101-6

Source DB:  PubMed          Journal:  J Chem Neuroanat        ISSN: 0891-0618            Impact factor:   3.052


  30 in total

1.  Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.

Authors:  Kathleen S Alexander; Hui-Qiu Wu; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2011-10-26       Impact factor: 4.530

2.  Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.

Authors:  Salma R I Ribeiz; Débora P Bassitt; Jony A Arrais; Renata Avila; David C Steffens; Cássio M C Bottino
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

Review 3.  Regulation of cortical acetylcholine release: insights from in vivo microdialysis studies.

Authors:  Jim R Fadel
Journal:  Behav Brain Res       Date:  2010-02-16       Impact factor: 3.332

4.  Transient inactivation of the neonatal ventral hippocampus permanently disrupts the mesolimbic regulation of prefrontal cholinergic transmission: implications for schizophrenia.

Authors:  Julie M Brooks; Martin Sarter; John P Bruno
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

Review 5.  Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.

Authors:  N Muller; M Schwarz
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

6.  F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.

Authors:  R Depoortère; A L Auclair; L Bardin; L Bruins Slot; M S Kleven; F Colpaert; B Vacher; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

Review 7.  Olanzapine Versus Risperidone in Children and Adolescents with Psychosis: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Lei Xia; Wen-Zheng Li; Huan-Zhong Liu; Rui Hao; Xiang-Yang Zhang
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-01-22       Impact factor: 2.576

Review 8.  Losing your inhibition: linking cortical GABAergic interneurons to schizophrenia.

Authors:  Melis Inan; Timothy J Petros; Stewart A Anderson
Journal:  Neurobiol Dis       Date:  2012-11-29       Impact factor: 5.996

9.  Effects of gastric vagotomy on visceral cell proliferation induced by ventromedial hypothalamic lesions: role of vagal hyperactivity.

Authors:  Yuri Kintaka; Toshimasa Osaka; Yoko Suzuki; Takeo Hashiguchi; Akira Niijima; Haruaki Kageyama; Takenoya Fumiko; Seiji Shioda; Shuji Inoue
Journal:  J Mol Neurosci       Date:  2009-05-20       Impact factor: 3.444

10.  Disruption of mesolimbic regulation of prefrontal cholinergic transmission in an animal model of schizophrenia and normalization by chronic clozapine treatment.

Authors:  Kathleen S Alexander; Julie M Brooks; Martin Sarter; John P Bruno
Journal:  Neuropsychopharmacology       Date:  2009-08-19       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.